SKI-349

SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA) . SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells[1][2].

Product Specifications

CAS Number

[727686-80-8]

UNSPSC

12352005

Target

Akt; mTOR; SphK

Type

Reference compound

Related Pathways

Immunology/Inflammation; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ski-349.html

Purity

99.58

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=C(N)N=C(NC2=CC=C(C=C2)OC)S1)C3=CC=C(C(OC)=C3)OC

Molecular Formula

C19H19N3O4S

Molecular Weight

385.44

References & Citations

[1]Hengst JA, et al. Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization. Bioorg Med Chem Lett. 2020 Oct 15;30 (20) :127453. |[2]Chen L, et al. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma. Tohoku J Exp Med. 2023 Dec 21.